Aprogen Medicines Inc. (007460.KS)
KRW 816.0
(-3.09%)
KRW 816.0
(-3.09%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -58.15 Billion | -113.49 Billion | -8.6 Billion | 22.53 Billion | -1.11 Billion | -1.48 Billion |
| Net Income | -55.61 Billion | -116.08 Billion | -12.5 Billion | -32.66 Billion | 18.32 Billion | -32.1 Billion |
| Depreciation & Amortization | 29.02 Billion | 28.39 Billion | 4.25 Billion | 4.3 Billion | 3.25 Billion | 2.03 Billion |
| Deferred income taxes | -58.15 Billion | - | -2.44 Billion | - | - | - |
| Stock-based compensation | 1.61 Billion | 707.67 Million | 2.44 Billion | - | - | - |
| Change in working capital | -15.86 Billion | -17.19 Billion | -23.61 Billion | 1.9 Billion | -8.64 Billion | -3.83 Billion |
| Other non-cash items | 40.83 Billion | -9.3 Billion | 23.25 Billion | 48.98 Billion | -14.04 Billion | 32.42 Billion |
| Investing Cash Flow | -43.45 Billion | 70.17 Billion | -32.46 Billion | -168.49 Billion | -151.41 Billion | -210.04 Billion |
| Investments in PPE | -54.88 Billion | -24.81 Billion | -2.11 Billion | -3.12 Billion | -8.17 Billion | -4.03 Billion |
| Acquisitions | 52.43 Million | 76.22 Billion | -12.69 Billion | 10.22 Billion | -38.53 Billion | -129 Billion |
| Investment purchases | -11.01 Billion | -15 Million | -347.17 Billion | -340 Billion | -299.5 Billion | -436.8 Billion |
| Sales/Maturities of investments | 14.16 Billion | 20.28 Billion | 425.98 Billion | 310.36 Billion | 245.52 Billion | 359.22 Billion |
| Other Investing Activities | 8.23 Billion | -1.5 Billion | -96.45 Billion | -145.96 Billion | -50.7 Billion | 573.83 Million |
| Financing Cash Flow | 94.29 Billion | 70.8 Billion | 6.61 Billion | 171 Billion | 164.22 Billion | 159.34 Billion |
| Debt repayment | -40.87 Billion | -7.79 Billion | -12.75 Billion | -171.78 Million | -9.21 Billion | -589.83 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -15.79 Billion | -113.9 Million | -64.94 Million | -3.21 Billion | - |
| Common Stock Issuance | 28.08 Billion | 30.96 Million | -73.34 Million | 132.87 Billion | -1.86 Billion | - |
| Other Financing Activities | 107.08 Billion | 94.35 Billion | 19.73 Billion | 38.43 Billion | 183.59 Billion | 159.93 Billion |
| Accounts receivables | 7.61 Billion | 8.23 Billion | -1.95 Billion | 5.62 Billion | -766.83 Million | -1.16 Billion |
| Accounts payables | -1.07 Billion | -1.85 Billion | 192.23 Million | -28.79 Million | -154.72 Million | -608.12 Million |
| Inventory | -5.02 Billion | -17.52 Billion | -4.26 Billion | 41.12 Million | -3.77 Billion | -889.48 Million |
| Other working capital | -17.38 Billion | -6.05 Billion | -17.58 Billion | -3.72 Billion | -3.95 Billion | -2.94 Billion |
| Cash at beginning of period | 43.06 Billion | 15.89 Billion | 96.61 Billion | 71.67 Billion | 59.92 Billion | 112.1 Billion |
| Cash at end of period | 35.68 Billion | 43.06 Billion | 62.37 Billion | 96.61 Billion | 71.67 Billion | 59.92 Billion |
| Capital Expenditure | -54.88 Billion | -24.81 Billion | -2.11 Billion | -3.12 Billion | -8.17 Billion | -4.03 Billion |
| Effect of forex changes on cash | -72.93 Million | -309.07 Million | 221.66 Million | -105.81 Million | 47.38 Million | 15.95 Million |
| Net cash flow / Change in cash | -7.38 Billion | 27.17 Billion | -34.23 Billion | 24.94 Billion | 11.74 Billion | -52.18 Billion |
| Free Cash Flow | -113.04 Billion | -138.31 Billion | -10.71 Billion | 19.41 Billion | -9.29 Billion | -5.52 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.86 Billion | -29.76 Billion | -55.61 Billion | 17.31 Billion | -30.65 Billion | -21.84 Billion |
| Depreciation & Amortization | 5.6 Billion | 5.9 Billion | 29.02 Billion | 6.79 Billion | 7.37 Billion | 7.24 Billion |
| Deferred income taxes | - | - | -58.15 Billion | -3.04 Billion | 11.06 Billion | 4.57 Billion |
| Stock-based compensation | - | - | 1.61 Billion | 42.08 Million | 1.4 Billion | 680.6 Million |
| Change in working capital | -1.81 Billion | 1.48 Billion | -15.86 Billion | 843.86 Million | -3.65 Billion | 2.61 Billion |
| Other non-cash items | -3.04 Billion | 24.8 Billion | 40.83 Billion | -31.81 Billion | -3.57 Billion | 1.09 Billion |
| Investing Cash Flow | -7.31 Billion | 276.47 Million | -43.45 Billion | -10.79 Billion | -14.71 Billion | -25.07 Billion |
| Investments in PPE | -2.02 Billion | -4.47 Billion | -54.88 Billion | -12.77 Billion | -17.27 Billion | -17.96 Billion |
| Acquisitions | -3.48 Billion | 3.51 Billion | 52.43 Million | 7.41 Million | 1.87 Million | 7.1 Billion |
| Investment purchases | -5.15 Billion | -3.35 Billion | -11.01 Billion | -4.01 Billion | 100 Million | -7.1 Billion |
| Sales/Maturities of investments | 5.57 Billion | 4.56 Billion | 14.16 Billion | 11.33 Billion | 1.53 Billion | 108.83 Million |
| Other Investing Activities | -5.28 Billion | 1.23 Billion | 8.23 Billion | -5.34 Billion | 929.73 Million | -7.21 Billion |
| Financing Cash Flow | 49.39 Billion | 1.26 Billion | 94.29 Billion | 34.09 Billion | 19.73 Billion | 28.85 Billion |
| Debt repayment | -206.04 Million | -1.55 Billion | -40.87 Billion | -46.95 Billion | -14.5 Billion | -7.55 Billion |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | -48.55 Million | -75 Million | 28.08 Billion | 28.09 Billion | -12.95 Million | 449.67 Thousand |
| Other Financing Activities | 49.59 Billion | -5 Million | 107.08 Billion | 52.94 Billion | 34.24 Billion | 36.4 Billion |
| Accounts receivables | - | - | 7.61 Billion | 9.75 Billion | 1.03 Billion | -1.75 Billion |
| Accounts payables | - | - | -1.07 Billion | -3.11 Billion | -5.25 Billion | 5.73 Billion |
| Inventory | - | - | -5.02 Billion | 3.95 Billion | -1.09 Billion | 5.21 Billion |
| Other working capital | -1.81 Billion | - | -17.38 Billion | -9.75 Billion | 1.66 Billion | -6.58 Billion |
| Cash at beginning of period | 27.92 Billion | 35.68 Billion | 43.06 Billion | 22.36 Billion | 35.32 Billion | 37.26 Billion |
| Cash at end of period | 62.51 Billion | 27.92 Billion | 35.68 Billion | 35.68 Billion | 22.36 Billion | 35.32 Billion |
| Capital Expenditure | -2.02 Billion | -4.47 Billion | -54.88 Billion | -12.77 Billion | -17.27 Billion | -17.96 Billion |
| Effect of forex changes on cash | 232.72 Million | 79.89 Million | -72.93 Million | -124.19 Million | 47.21 Million | -90.21 Million |
| Net cash flow / Change in cash | 34.58 Billion | -7.75 Billion | -7.38 Billion | 13.32 Billion | -12.96 Billion | -1.93 Billion |
| Free Cash Flow | -9.75 Billion | -13.84 Billion | -113.04 Billion | -22.63 Billion | -35.31 Billion | -23.59 Billion |
019685
LH-R
001275
HERB
TCPC
310210